公开(公告)号：US20190183897A1

公开(公告)日：2019-06-20

申请号：US16274573

申请日：2019-02-13

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Hiroaki OCHIIWA ,  Hiroshi HIRAI

IPC分类号： A61K31/519 ,  A61K31/5377 ,  C07D487/04 ,  A61K31/437

CPC分类号： A61K31/519 ,  A61K31/437 ,  A61K31/5377 ,  C07D487/04

摘要： The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.

公开(公告)号：US20160193210A1

公开(公告)日：2016-07-07

申请号：US14905420

申请日：2014-07-17

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Hiroaki OCHIIWA ,  Hiroshi HIRAI

IPC分类号： A61K31/519

摘要： The problem to be solved by the present invention is to provide a potent and highly selective novel FGFR inhibitor, and an antitumor agent having reduced side effects, such as increased blood phosphorus levels, while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) or a salt thereof that is used so that the 3,5-disubstituted benzene alkynyl compound or a salt thereof is administered on an administration schedule of at least twice a week and a dosing interval of at least one day.

摘要翻译： 本发明要解决的问题是提供一种有效和高度选择性的新型FGFR抑制剂和具有降低的副作用的抗肿瘤剂，例如增加血磷水平，同时保持FGFR抑制剂的抗肿瘤作用。 本发明提供一种抗肿瘤剂，其包含由式（I）表示的3,5-二取代苯炔基化合物或其盐，其用于使得3,5-二取代的苯炔基化合物或其盐在给药 每周至少两次的时间表和至少一天的给药间隔。